Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-975: Pembrolizumab vs placebo with definitive chemoradiotherapy in esophageal carcinoma
2022-501531-16-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC) and esophagogastric junction cancer comparing Pembrolizumab + dCRT with Placebo + dCRT (2 arms). Primary endpoints: Overall Survival and Event-free Survival. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2022-501531-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501531-16-00.